Eledon Pharmaceuticals is poised to revolutionize kidney transplant care with tegoprubart, targeting a $6B market. Read why ...

Results from phase 2 trials appear to support the use of chemotherapy-free regimens in patients with osimertinib-resistant NSCLC.

Taylor Grenda is excited to be a part of the FOX 5 weather team in Washington, DC. Most recently, Taylor was a meteorologist at WBAL in Baltimore, MD where she spent 5 years forecasting anything ...

There are currently no proven therapies that reduce cisplatin-induced acute kidney injury (AKI) in patients with cancer.

The use of an investigational topical BRAF-inhibiting gel appeared to be effective in treating acneiform rash in patients ...

Explore the latest NSCLC new treatments in development, including candidates aimed at tackling hard-to-treat, late-stage lung ...

Topical BRAF inhibitor LUT014 gel significantly reduces acneiform rash from anti-EGFR therapies in patients with colorectal ...

Greenfire Resources Ltd.’s GFR share price has dipped by 5.70%, which has investors questioning if this is right time to buy.

YAP, a protein known to help cancer cells survive treatment, behaves very differently in cell culture models depending on how they are grown in the lab, highlighting the importance of mimicking tumour ...

ORIC Pharmaceuticals, Inc.’s ORIC share price has surged by 7.27%, which has investors questioning if this is right time to ...

A new topical gel called LUT014 successfully reduced the severity of a painful acne‐like rash that commonly occurs as a side effect of targeted therapy with epidermal growth factor receptor (EGFR) ...

Zongertinib, an oral therapy shown to have strong responses in patients previously treated for HER2 -mutated non–small cell ...